PVG Asset Management Corp Invests $773,000 in Immuneering Corporation $IMRX

PVG Asset Management Corp bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 146,661 shares of the company’s stock, valued at approximately $773,000. PVG Asset Management Corp owned 0.23% of Immuneering as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after purchasing an additional 4,458 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Immuneering in the fourth quarter valued at approximately $33,000. Southport Management L.L.C. increased its position in shares of Immuneering by 1.8% in the fourth quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock valued at $1,826,000 after buying an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Immuneering by 46.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after buying an additional 6,196 shares in the last quarter. Finally, LPL Financial LLC raised its stake in shares of Immuneering by 30.0% during the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock worth $192,000 after buying an additional 6,725 shares during the period. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IMRX. Needham & Company LLC increased their target price on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Cantor Fitzgerald started coverage on shares of Immuneering in a report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target for the company. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Immuneering in a report on Tuesday, May 19th. Finally, Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Immuneering Price Performance

Shares of Immuneering stock opened at $4.13 on Monday. The stock has a market capitalization of $267.21 million, a price-to-earnings ratio of -3.53 and a beta of 0.43. The business has a 50-day moving average of $4.66 and a 200 day moving average of $4.99. Immuneering Corporation has a 12 month low of $2.90 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. Equities research analysts anticipate that Immuneering Corporation will post -1.09 earnings per share for the current year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.